With Geron Deal Done, AngioChem Turns To Its Own Pipeline
This article was originally published in The Pink Sheet Daily
A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.
You may also be interested in...
The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.
A brave face: Celldex execs say they are ready and able to take brain cancer vaccine CDX-110 into Phase III without a Big Pharma partner.
In terms of oncology alliances, 2009 is shaping up as slower than the previous three years, but the number of significantly priced deals has not decreased greatly